Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Will this out-of-favor EV charging stock ever recover?
Multiple growth drivers and a trillion-dollar revenue opportunity could help this company maintain its impressive growth over the next few years.